The most stringent regulation of mobile medical treatment: a large number of online medical companies will die
After harassing for more than half a month, the voice from the regulatory layer, for the Internet medical companies on the eve of the change, temporarily took a reassurance.
This month, a letter from the General Office of the National Health and Family Planning Commission on the Consultation on the Administration of Internet Diagnosis and Treatment (Trial) (Draft for Comment) and Opinions on Advancing the Development of Internet Medical Services (Request for Comments) (hereinafter referred to as "Opinions" spread on the Internet, a total of 39 regulations, from the requirements of Internet access to medical services, medical institutions practice rules, Internet diagnosis and treatment activities and related legal liability details, put forward specific requirements.
In summary, the new regulations may increase the threshold for online doctor consultation and tighten the scope of online medical treatment, which will have a major impact on the Internet medical industry . Some practitioners have commented on this. The document of the Health Planning Commission will make some Internet medical institutions cry first.
The main reason for the industry to feel uneasy is from Articles 4, 7, 9, 14 and 23 of the Opinions. According to these provisions, the Internet diagnosis and treatment activities have become the organization of the Internet + with medical institutions as the core. In a way, the doctors' sources on various Internet platforms are greatly reduced, and the difficulty of organization is enhanced from the supply side.
To put it simply, the current consultation is the main business of many Internet medical startups. Under the new regulations, most online consultation services will be closed due to violations. Therefore, whether the documents will come true or not, For medical companies, it is equivalent to a life and death problem.
Faced with various questions, recently, the relevant staff of the National Health and Family Planning Commission responded to the "Draft for Comment" circulating on the Internet. "This document has not yet been released publicly, and it is only a draft for comments. There will definitely be changes in the future."
This response indicates that there is still room for manoeuvre in the previous regulations, which is good news for some Internet medical companies facing life and death.
However, it is foreseeable that the management of Internet medical care by the regulatory authorities is gradually improving and standardizing. The days that the industry participants were able to make new attempts were coming to an end because they were still not clearly defined by the relevant departments during the groping period.
With the supervision of Internet medical treatment entering the deep water period, this industry, which has been highly anticipated by many entrepreneurs and investors, has now reached the crossroads of destiny.
Shuffle will arrive
Online consultation was once an important fulcrum for the mobile medical industry.
As a player who entered the mobile medical industry earlier, Dr. Chun Yu, who was founded in 2011, harvested his first users through an online consultation, and then launched a private doctor service. After several years of development, the mobile medical industry has now gathered a large number of enterprises covering a variety of business directions, and online consultation is a standard feature of many mobile medical applications for ordinary users.
In April this year, the Lilac Garden, which was established 17 years ago, announced that its medical service APP, Dr. Clove, has connected all the functional modules of its WeChat-based medical payment Q&A product to the “Clove Doctor†in the latest version 6.0. This means that as an established Internet medical startup, Lilac Garden has finally entered the online consultation/information business.
The RT-PCR Test Reagent Kit is a real-time, RT-PCR test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in oropharyngeal and nasopharyngeal swab specimens from individuals suspected of COVID-19 by their healthcare provider. This test is also for use with anterior nasal swab specimens that are collected using the COVID-19 Test Collection Kit when used consistent with its authorization.
Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in the upper respiratory specimens during the acute phase of infection.
Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status.
Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease.
Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations,patient history,and epidemiological information.
PCR test Kit,PCR testing Kit,PCR detection kit,RT-PCR test reagent kit,RT-PCR test reagent
Shenzhen Uni-medica Technology Co.,Ltd , https://www.unimed-global.com